Osteocalcin γ-Carboxylation by Vitamin K2, Collagen Crosslink Architecture, and Phosphatidylserine Acetylcholine Release in Post-Menopause

[Image: Vitamin K cycle schematic: K2 hydroquinone → GGCX-mediated γ-carboxylation → K 2,3-epoxide → VKORC1 reduction back to KH2, with osteocalcin (bone mineralization) and MGP (arterial calcification inhibition) as dual carboxylation targets]

Vitamin K2 (menaquinone) serves as the obligate cofactor for vitamin K-dependent γ-carboxylase (GGCX), the enzyme that catalyzes γ-carboxylation of glutamate residues to γ-carboxyglutamate (Gla) residues in K-dependent proteins. This post-translational modification — addition of a carboxyl group to glutamate side chains — confers calcium-binding capacity on Gla proteins, enabling their biological function. The γ-carboxylation reaction oxidizes vitamin K hydroquinone (KH2) to vitamin K 2,3-epoxide; the epoxide is recycled back to KH2 by VKORC1 (vitamin K epoxide reductase complex, subunit 1) — the same enzyme inhibited by warfarin.

Two Gla proteins are directly relevant to post-menopausal physiology: osteocalcin (bone Gla protein, BGP) and matrix Gla protein (MGP). Fully carboxylated osteocalcin binds hydroxyapatite mineral crystals in bone matrix via its three Gla residues, coupling mineral deposition to the collagen scaffold and enabling osteoblast-directed mineralization. Undercarboxylated osteocalcin (ucOC) — elevated in K2 deficiency — circulates freely and acts as an endocrine hormone with metabolic effects (insulin sensitization, adiponectin stimulation), but does not contribute to bone mineral density. MGP, expressed in vascular smooth muscle cells, is the primary inhibitor of arterial calcification: carboxylated MGP binds calcium phosphate crystals and prevents their deposition in arterial walls. Undercarboxylated MGP (ucMGP) — a sensitive K2 deficiency biomarker — is strongly associated with arterial stiffness, coronary calcification, and cardiovascular mortality in prospective cohort studies.

[Image: MK-4 vs MK-7 plasma concentration curves over 24 hours: MK-4 three-dose profile vs MK-7 single-dose profile with sustained above-threshold concentration, showing carboxylation threshold line and osteocalcin/MGP saturation requirements]

Menaquinones exist in multiple isoforms differentiated by the length of their polyisoprene side chain (MK-4 through MK-13). The two clinically relevant supplemental forms are MK-4 (four isoprene units, synthetic, from geranylgeraniol) and MK-7 (seven isoprene units, naturally derived from fermented natto or Bacillus subtilis synthesis). Their pharmacokinetics differ substantially and determine dosing strategy. MK-4 has a plasma half-life of approximately 1–2 hours and requires three-times-daily dosing (typically 1,000–1,500μg/day split doses) to maintain carboxylase-saturating tissue concentrations. MK-7 has a plasma half-life of approximately 72 hours, enabling once-daily dosing at 90–360μg/day to maintain supraphysiological K2 concentrations throughout the full 24-hour period.

The longer half-life of MK-7 translates into superior 24-hour carboxylation of both osteocalcin and MGP in comparative pharmacodynamic studies. The Rotterdam Study cohort (n=4,807) demonstrated that highest-tertile MK-7 dietary intake was associated with a 57% reduction in cardiovascular mortality and 52% reduction in aortic calcification over 10 years. MK-4, despite its shorter half-life, has stronger RCT evidence specifically for fracture reduction in Japanese populations (menatetrenone 45mg/day trials). In practice, MK-7 at 180–360μg/day is the preferred post-menopausal supplemental form for once-daily dosing convenience and sustained osteocalcin/MGP carboxylation. Functional K2 status assessment via ucOC (serum undercarboxylated osteocalcin) or ucMGP provides a direct pharmacodynamic biomarker for dose adequacy.

[Image: Bone matrix collagen scaffold diagram: type I collagen fibril triple helix structure with pyridinoline (Pyd) and deoxypyridinoline (Dpd) crosslink positions labeled, LOX enzyme site indicated, and vitamin C prolyl/lysyl hydroxylase cofactor function annotated]

Bone is approximately 35% organic matrix by weight, with type I collagen fibrils constituting 90% of this organic component. Collagen quality — specifically the density and pattern of intermolecular crosslinks — determines bone's post-yield ductility and fracture resistance independent of mineral density. The two primary mature collagen crosslinks in bone are pyridinoline (Pyd, hydroxylysyl-pyridinoline) and deoxypyridinoline (Dpd), formed by LOX (lysyl oxidase)-catalyzed oxidation of lysine/hydroxylysine residues followed by Amadori rearrangement. These trivalent crosslinks connect tropocollagen triple helices within and between fibrils, providing the tensile strength that prevents brittle fracture.

In post-menopausal osteoporosis, accelerated bone turnover degrades mature pyridinoline-crosslinked collagen before replacement collagen can develop adequate crosslink density — a qualitative deficit that coexists with quantitative mineral density loss. Vitamin C (ascorbate, 200–500mg/day) is the obligate cofactor for prolyl hydroxylase and lysyl hydroxylase — the enzymes that hydroxylate proline and lysine residues in procollagen, enabling both triple helix stability and crosslink formation. Silicon (as orthosilicic acid, 10–25mg/day) stimulates collagen type I synthesis in osteoblasts through upregulation of HIF-1α-responsive collagen gene promoters. Hydrolyzed collagen peptides (10g/day) provide hydroxyproline-proline dipeptide sequences that stimulate osteoblast collagen synthesis via integrin-mediated cell signaling. These nutritional inputs address the collagen scaffold quality dimension that bisphosphonate therapy — focused exclusively on osteoclast suppression — does not.

[Image: Synaptic vesicle exocytosis mechanism: PS inner leaflet concentration via flippase → negative surface charge enabling SNARE complex (synaptobrevin/SNAP-25/syntaxin) assembly → ACh release, with PS depletion in aging labeled and supplementation restoration pathway indicated]

Cognitive decline in post-menopause — manifesting as processing speed reduction, working memory impairment, and verbal memory deficits — involves multiple mechanisms including hypoestrogenic neurotrophin reduction (BDNF, NGF), reduced cerebral blood flow, and impaired cholinergic neurotransmission. Phosphatidylserine (PS) addresses the latter at the synaptic vesicle level through a well-characterized membrane phospholipid mechanism.

Synaptic vesicle exocytosis requires a series of SNARE protein interactions (synaptobrevin-SNAP-25-syntaxin complex) that are facilitated by membrane fluidity and negative surface charge at the inner leaflet of the presynaptic membrane. PS, concentrated in the inner leaflet by ATP-dependent aminophospholipid translocase (flippase) activity, provides this negative surface charge and promotes membrane curvature required for vesicle fusion. In aging neurons, PS content of neuronal membranes declines due to reduced PS synthesis (via PS synthase 1/2) and impaired flippase-mediated asymmetric distribution. PS supplementation at 300mg/day (from soy-derived phosphatidylserine) restores membrane PS content, improving the biophysical conditions for vesicle-membrane fusion and consequently acetylcholine release kinetics. RCTs at 300mg/day have demonstrated improvements in verbal learning, memory consolidation, and cognitive function scores in aged adults, with effect sizes (SMD approximately 0.35–0.55) that while modest are mechanistically specific — unlike the non-specific cognitive benefits claimed for most nootropic supplements.